ROYALTY PHARMA

Thermo Fisher's Oncomine receives FDA approval as companion diagnostic for grade 2 IDH-mutant glioma, identifying patients eligible for Servier's Voranigo treatment. Voranigo, a once-daily IDH1/IDH2 inhibitor, is the first targeted therapy for this condition, with projected sales of $37m by 2030.

Thermo Fisher Scientific's Oncomine gains FDA approval as a companion diagnostic for grade 2 IDH-mutant glioma, identifying patients eligible for Servier Pharmaceuticals' Voranigo treatment. Voranigo, a once-daily IDH1/IDH2 inhibitor, is the first targeted therapy for this condition.

PureTech Health's KarXT, now marketed as Cobenfy, receives FDA approval for treating schizophrenia in adults, triggering $29m in payments from Royalty Pharma and Karuna Therapeutics. Cobenfy, developed by combining xanomeline with trospium chloride, aims to address tolerability issues in neuropsychiatric treatments. PureTech anticipates 2% royalties on net annual sales exceeding $2bn, with Cobenfy's success generating $1.1bn for the company, enabling self-funding of its pipeline, including LYT-100 for idiopathic pulmonary fibrosis.

PureTech-invented KarXT receives FDA approval for schizophrenia treatment, triggering $29M in milestone payments and potential future royalties. KarXT, now marketed as Cobenfy by Bristol Myers Squibb, is the first new drug mechanism for schizophrenia in over 50 years.

PureTech Health announced FDA approval of KarXT for schizophrenia, triggering $29 million in milestone payments from Royalty Pharma and Karuna Therapeutics, acquired by Bristol Myers Squibb in 2024. KarXT will be marketed as Cobenfy, the first new drug mechanism for schizophrenia in over 50 years.

BRAIN Biotech AG secures up to EUR 128.88 million in a royalty monetization deal with Royalty Pharma for deucrictibant, an investigational compound. The deal includes an upfront payment of EUR 18.41 million and potential milestones.

BRAIN Biotech AG secures EUR 128.88 million in royalty monetization for deucrictibant, with EUR 18.41 million upfront and potential milestones of EUR 110.47 million. The deal accelerates the company’s goal to lead in the industrial enzyme market, focusing on food, beverage, and life sciences.

BRAIN Biotech AG concludes royalty monetization deal with Royalty Pharma for up to EUR 128.88 million on investigational pharma compound deucrictibant, receiving an upfront payment of EUR 18.41 million, potential regulatory milestones of up to EUR 18.42 million, and long-term sales related milestones of up to EUR 92.05 million.

Agios Pharmaceuticals received orphan drug designation (ODD) from the FDA for tebapivat to treat myelodysplastic syndromes (MDS). The designation offers benefits like tax credits, fee exemptions, and market exclusivity. Agios aims to deliver the first oral therapy addressing anaemia in lower-risk MDS, affecting around 75,000-80,000 patients in key markets. The company focuses on developing therapies for rare diseases, with lead asset mitapivat, a PK activator, previously receiving ODD for PK deficiency, thalassaemia, and sickle cell disease.